UroGen Pharma Ltd.
NASDAQ · URGN·Princeton, NJ·Small-cap·Approved
Commercial-stage biotech focused on urothelial and bladder cancers using its proprietary RTGel reverse-thermal hydrogel technology for sustained local drug delivery. Markets JELMYTO for upper tract urothelial cancer and ZUSDURI for non-muscle invasive bladder cancer.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| UroGen Corporate Presentation March 2026 | Corporate overview | March 1, 2026 | 30 |